Shan Yau
Sr Research Associate at Xenoport Inc
Shan Yau's Professional Contact Details
Email (Verified)
****@arborpharma.com
HQ
(408) 616-7200
Location
San Francisco, California, US
Company
Xenoport Inc
Person Seniority
senior
Shan Yau's Current Company Details
XenoPort, Inc. is a biopharmaceutical company focused on developing and commercializing a portfolio of internally discovered product candidates for the potential treatment of neurological disorders. H...
XenoPort, Inc. is a biopharmaceutical company focused on developing and commercializing a portfolio of internally discovered product candidates for the potential treatment of neurological disorders. Horizant® (gabapentin enacarbil) Extended-Release Tablets is approved and being marketed in the United States by XenoPort. Regnite® (gabapentin enacarbil) Extended-Release Tablets is approved and being marketed in Japan by Astellas Pharma Inc. XenoPort holds all other world-wide rights to gabapentin enacarbil. XenoPort's pipeline of product candidates includes potential treatments for patients with Parkinson's disease, relapsing-remitting multiple sclerosis and psoriasis.
Public Symbol
XNPT
Founded Year
1999
Organization Website
xenoport.com
Organization Languages
English
Organization Revenue
46900
Current Technologies
outlook
apache
google analytics
mobile friendly
pharmaceuticals
medical
Shan Yau's Work History and Education
XenoPort, Inc.
Sr Research Associate
Present
Colleagues at Xenoport Inc
Prospect on LinkedIn
Find emails on Linkedln, Sales Navigator, AngelList, CrunchBase, Google etc.
Download
Extension
Other people in our database: